Trial Profile
A study investigating the impact of ipilimumab on body composition parameters and the effect of body composition parameters on ipilimumab toxicity and survival in patients with metastatic melanoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 03 Apr 2017
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary)
- Indications Malignant melanoma
- Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
- 03 Apr 2017 New trial record